KARYOPHARM THERAPEUTICS INC (KPTI)
US48576U1060 - Common Stock
Overall KPTI gets a fundamental rating of 2 out of 10. We evaluated KPTI against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of KPTI have multiple concerns. While showing a medium growth rate, KPTI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
KPTI had negative earnings in the past year.
In the past year KPTI has reported a negative cash flow from operations.
In the past 5 years KPTI always reported negative net income.
In the past 5 years KPTI always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of KPTI (-46.17%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.17% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-48.77%
ROA(5y)-55.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 95.85%, KPTI belongs to the best of the industry, outperforming 96.28% of the companies in the same industry.
KPTI's Gross Margin has been stable in the last couple of years.
KPTI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.85% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.3%
GM growth 5YN/A
2. Health
2.1 Basic Checks
KPTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KPTI has been increased compared to 1 year ago.
The number of shares outstanding for KPTI has been increased compared to 5 years ago.
The debt/assets ratio for KPTI is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -11.81, we must say that KPTI is in the distress zone and has some risk of bankruptcy.
KPTI has a worse Altman-Z score (-11.81) than 77.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -11.81 |
ROIC/WACCN/A
WACC4.43%
2.3 Liquidity
A Current Ratio of 3.00 indicates that KPTI has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.00, KPTI is doing worse than 64.78% of the companies in the same industry.
A Quick Ratio of 2.93 indicates that KPTI has no problem at all paying its short term obligations.
With a Quick ratio value of 2.93, KPTI is not doing good in the industry: 64.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3 | ||
| Quick Ratio | 2.93 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 40.15% over the past year.
The Revenue has been growing slightly by 1.74% in the past year.
KPTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 36.96% yearly.
EPS 1Y (TTM)40.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
Revenue 1Y (TTM)1.74%
Revenue growth 3Y10.55%
Revenue growth 5Y36.96%
Sales Q2Q%7.7%
3.2 Future
Based on estimates for the next years, KPTI will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.21% on average per year.
Based on estimates for the next years, KPTI will show a quite strong growth in Revenue. The Revenue will grow by 19.66% on average per year.
EPS Next Y49.19%
EPS Next 2Y19.14%
EPS Next 3Y17.72%
EPS Next 5Y14.21%
Revenue Next Year3.41%
Revenue Next 2Y5.96%
Revenue Next 3Y11.02%
Revenue Next 5Y19.66%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
KPTI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KPTI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KPTI's earnings are expected to grow with 17.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.14%
EPS Next 3Y17.72%
5. Dividend
5.1 Amount
KPTI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KARYOPHARM THERAPEUTICS INC
NASDAQ:KPTI (12/20/2024, 8:21:28 PM)
After market: 0.6483 +0.01 (+2.09%)0.635
-0.01 (-2.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners56.7%
Inst Owner Change-11.66%
Ins Owners0.5%
Ins Owner Change-0.18%
Market Cap79.57M
Analysts83.08
Price Target4.59 (622.83%)
Short Float %16.11%
Short Ratio22.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)76.14%
Min EPS beat(2)3.03%
Max EPS beat(2)149.25%
EPS beat(4)3
Avg EPS beat(4)36.09%
Min EPS beat(4)-13.96%
Max EPS beat(4)149.25%
EPS beat(8)5
Avg EPS beat(8)19.62%
EPS beat(12)9
Avg EPS beat(12)32.34%
EPS beat(16)11
Avg EPS beat(16)24.42%
Revenue beat(2)2
Avg Revenue beat(2)8.28%
Min Revenue beat(2)0.62%
Max Revenue beat(2)15.94%
Revenue beat(4)2
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-6.55%
Max Revenue beat(4)15.94%
Revenue beat(8)4
Avg Revenue beat(8)-0.17%
Revenue beat(12)8
Avg Revenue beat(12)21.36%
Revenue beat(16)10
Avg Revenue beat(16)18.37%
PT rev (1m)3.28%
PT rev (3m)3.28%
EPS NQ rev (1m)3.36%
EPS NQ rev (3m)12.86%
EPS NY rev (1m)6.97%
EPS NY rev (3m)5.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.79
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.96
FCFYN/A
OCF(TTM)-0.96
OCFYN/A
SpS1.18
BVpS-1.27
TBVpS-1.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46.17% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 95.85% | ||
| FCFM | N/A |
ROA(3y)-48.77%
ROA(5y)-55.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.3%
GM growth 5YN/A
F-Score2
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 57.52% | ||
| Cap/Sales | 0.13% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3 | ||
| Quick Ratio | 2.93 | ||
| Altman-Z | -11.81 |
F-Score2
WACC4.43%
ROIC/WACCN/A
Cap/Depr(3y)15.31%
Cap/Depr(5y)16.61%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.33%
EPS Next Y49.19%
EPS Next 2Y19.14%
EPS Next 3Y17.72%
EPS Next 5Y14.21%
Revenue 1Y (TTM)1.74%
Revenue growth 3Y10.55%
Revenue growth 5Y36.96%
Sales Q2Q%7.7%
Revenue Next Year3.41%
Revenue Next 2Y5.96%
Revenue Next 3Y11.02%
Revenue Next 5Y19.66%
EBIT growth 1Y-0.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-23.67%
OCF growth 3YN/A
OCF growth 5YN/A